Evidence of meeting #29 for Science and Research in the 45th Parliament, 1st session. (The original version is on Parliament’s site, as are the minutes.) The winning word was companies.

A recording is available from Parliament.

On the agenda

Members speaking

Before the committee

Tessari L'Allié  Founder and Executive Director, AI Governance and Safety Canada
Michaud  President and Chief Executive Officer, BioCanRx
Annan  President and Chief Executive Officer, Genome Canada
Morin  President and Chief Executive Officer, Federation for the Humanities and Social Sciences
Doyle  Executive Director, Tech-Access Canada
Chan  Associate Vice-President and Vice-Provost, Strategic Initiatives, University of Toronto

Jennifer McKelvie Liberal Ajax, ON

Thank you, Madam Chair.

My first questions are for Dr. Annan.

Thank you for coming today.

I took note of your four recommendations. Today is about governance, so I'm just wondering whether you can speak to Genome Canada's governance and oversight. Do you have a board? What does that look like?

4:10 p.m.

President and Chief Executive Officer, Genome Canada

Robert Annan

There are a few layers of governance, I think. We are an independent, not-for-profit organization with an independent board of directors, subject to the Canada Not-for-profit Corporations Act. As such, we have to exhibit good governance, as well as publish audited financials every year. We have an annual report that outlines all of our activities, lists of projects, and so on and so forth. We also have an international science and industry advisory committee that provides the board with guidance on best practices and trends internationally when it comes to the kind of research we support. We have all of the elements of good governance that you would expect in any privately held organization.

On top of that, we are subject to the terms and conditions of our funding agreement with the Government of Canada, which generally follows Treasury Board guidelines. We are subject not only to quarterly reporting on financials but also to regular audits and to value-for-money audits, as well as to a regular five-year impact assessment, which is tied to our funding renewals.

There's a second layer. Because we have funding from the provinces, we are also indirectly subject to provincial oversight through the co-funding received through our regional genome centres.

Then, of course, we have governance internally on the actual dispensing of funds at the project level. We have two layers of peer review: for scientific and technical merit and for impact. We also subject all projects to independent financial assessments before the flowing of funds. They are then overseen by governance committees of experts, with quarterly reporting and milestone-driven funding arrangements.

Jennifer McKelvie Liberal Ajax, ON

You spoke to the need for a science strategy, mission-driven research, coordination of priorities and ensuring uptake and commercialization.

However, on that, I think my colleague also touched on the importance of academic freedoms. For example, in the stem cell space, researchers have done a very good job at using a technology with a lot of possibility for good and for human health. I know we have other technologies at the forefront where we haven't necessarily developed these sorts of ethical frameworks, for example, synthetic biology.

What sort of scientific oversight do you see, and how do you see people coming together, in addition to government regulation, by bringing self-regulation around these very rapidly evolving technologies where they are at the front and centre?

4:10 p.m.

President and Chief Executive Officer, Genome Canada

Robert Annan

Thanks for the question because it actually relates to some of the comments my fellow witness was just making around AI.

Generally speaking, as a society, and certainly when we think about creating positive economic impact, it's easy to focus on getting money into the hands of the inventors and the people who are going to really push the technology to the forefront. I really do think it's important that we are always also supporting work by independent researchers in the space who are working around ethics, law and policy to be able to support the effective context that's required for a lot of these transformational technologies. A lot of that comes from the communities themselves.

At Genome Canada, we've always spent roughly 10% of our budget in social sciences and humanities research. That's to help smooth the adoption of these technologies by understanding social needs and public acceptance and the ethical and legal dimensions around that research. I think we should do more of that. I think we should guard against the bias towards the technology side and make sure we're doing some of that work.

I do think it's somewhere the government doesn't necessarily need to do the work, but can provide leadership by being able to point the direction—though not at the level, as your colleague mentioned, of dictating what science should and shouldn't be done. Important questions should be asked. What sorts of outcomes are we really driving as a society? What do we want AI to do for Canada? What do we want genomics to do for Canada? What are the kinds of outcomes we see? Then organizations like ours can mobilize those experts in pursuit of those goals.

Jennifer McKelvie Liberal Ajax, ON

Thank you.

Dr. Michaud, you spoke very well to the importance of the strategic science fund. I know there are a lot of wonderful organizations covered by that fund.

Bringing this back to governance and oversight of that fund, it's kind of always one-off funding and people coming and going.

How can we better coordinate within that strategic science fund? For instance, who is working in that fund and how are they working together? How can we make sure that we're maximizing the success of all of that work?

The Chair Liberal Salma Zahid

Make it a 15-second answer, please.

4:15 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

Again, at BioCanRx we are very focused on key deliverables: the number of clinical trials taking place in Canada and the number of patients treated. We communicate these results to our SSF secretariat, which then assembles all of the results from similar SSF recipients.

When we're thinking about different sectoral strategies, there's really a need to develop goalposts for where Canada wants to be and where we want to go. I think we took a first stab at this with a biomanufacturing and life sciences strategy—

The Chair Liberal Salma Zahid

I'm sorry to interrupt, but could you wind up quickly?

4:15 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

I can follow up.

The Chair Liberal Salma Zahid

Thank you.

We will now go to MP Beaulieu for two and a half minutes.

Please go ahead.

Mario Beaulieu Bloc La Pointe-de-l'Île, QC

Thank you, Madam Chair.

Mr. Annan, essentially, based on the findings regarding fragmented data governance, what type of national, federated or centralized architecture do you recommend for the secure sharing of genomic and health data? Furthermore, what public performance indicators do you recommend?

4:15 p.m.

President and Chief Executive Officer, Genome Canada

Robert Annan

I'm going to give my answer in English, if you don't mind.

Globally, there is a tension between how to ensure we have effective oversight and privacy of data, especially human patient data, and the recognition that bringing that data together allows us to find the treatments, diagnostics and so on that so many patients need.

Best practices are still being developed, but we actually have a wonderful organization based here in Canada called the Global Alliance for Genomics and Health. It is an international organization that sets standards for how to effectively share data across jurisdictions while protecting those privacies.

Generally speaking, there's a bit of a combination between federating that data so that the data are being held in different locations, often at a provincial level when it comes to hospital data and so on, while at the same time recognizing that some data needs to be combined, and identifying the set of what we call "minimal metadata". This is patient data that ideally won't identify individuals but can be used to make the data more useful.

Mario Beaulieu Bloc La Pointe-de-l'Île, QC

Thank you.

I have a more general question. It has been noted that there's no independent body in Canada to systematically assess the distribution of research funding by discipline, institution, language, or other criteria. Do you have any recommendations in this regard?

4:15 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

Is the question for me or for everyone?

Mario Beaulieu Bloc La Pointe-de-l'Île, QC

It's for you, Dr. Michaud.

4:15 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

The answer is yes. All my colleagues here as witnesses and I would need a governance system capable of managing the various investments or, at the very least, reporting on the various investments made across Canada. This would also enable us to evaluate the performance of research investments.

I also want to reiterate that researchers in Canada are absolutely exceptional, and their work is excellent. We're recognized internationally for the quality of the research we conduct. Right now, we're really talking about how to move to the next stage and leverage all the results we have.

Do we need to carefully consider what such an organization might look like, what it could do, and what kind of governance it might have? Yes, absolutely.

The Chair Liberal Salma Zahid

Thank you. Your time is up.

We will now proceed with MP Ho for five minutes.

Please go ahead.

4:20 p.m.

Conservative

Vincent Ho Conservative Richmond Hill South, ON

Thank you, Madam Chair.

My first set of questions is for Dr. Michaud of BioCanRx.

The Liberal government recently announced a series of cuts to science funding. It's affecting over a dozen science organizations. One of them is BioCanRx.

Can you walk the committee through how some of these recently announced funding reductions will impact BioCanRx's current research portfolio and future research ambitions, particularly those around cancer immunotherapy projects?

4:20 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

We're still determining how we will navigate these cuts. Again, we are looking to work with government stakeholders in order to potentially alleviate the extent of these cuts here. We are in the process of launching a competition at BioCanRx, in addition to meeting with government stakeholders and working with a number of other not-for-profit stakeholders and charities in the cancer space to see how we can mitigate these cuts to BioCanRx.

It's still early days as we try to determine the overall impact of the cuts. The worst-case scenario is that there could be projects, potentially, that are not funded in that very critical development space. Ultimately, the impact could be that a research team isn't able to file with Health Canada for a future clinical trial application because that funding wasn't available to fund the development.

4:20 p.m.

Conservative

Vincent Ho Conservative Richmond Hill South, ON

That's really unfortunate.

This Liberal government spent $19 billion—that's “billion” with a B—on consultants last year alone. Those consultants aren't doing any research, most likely. At least, it's not the groundbreaking work the folks at BioCanRx are doing.

You talked about clinical trials. Can you quantify the downstream impact that these funding cuts could have on patients, particularly those who rely on the clinical trials or emerging therapies that BioCanRx helps support?

4:20 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

BioCanRx is committed to bringing forward made-in-Canada therapies. The pace of research worldwide is accelerating at an incredible pace. The goal of BioCanRx is to fund development in future clinical trials so we're able to capitalize on those new discoveries and new treatments.

The products we work with are entirely novel and really represent a chance for cancer patients in Canada to access the best that science has to offer them. These are patients who have run out of options, who have exhausted the standard of care and who are looking to clinical trials in order to, perhaps, survive the disease they are confronted with. In our previous funding portfolio, we funded CAR T programs and had patients access therapies that were previously unavailable in Canada. I'm happy to report that they are four years post treatment, and they are still alive and doing very well as a result of the work of our network. Anything that interferes with bridging this gap....

Yes, ultimately, the downstream impact will be on the number of clinical trials that are supporting made-in-Canada solutions.

4:20 p.m.

Conservative

Vincent Ho Conservative Richmond Hill South, ON

The Liberal government kept singing the rhetoric that it's going to somehow spend less and invest more, and we're seeing the opposite. It's spending a record $78-billion budget deficit. It doesn't seem like it's making the 15% cuts; it hasn't met that target yet in terms of day-to-day operational spending.

Then, on the investing more part, it seems like in this aspect, again, it's doing the opposite of what it's saying. It is actually investing less in science.

We've seen this government spend money on things like $8 million for gender-just, low-carbon rice in Vietnam and $22 million for beans for women for empowerment in the Democratic Republic of the Congo.

What kinds of conversations, if any, did BioCanRx have with the federal government prior to these cuts? Were these cuts thrown at you so that you just had to deal with them?

4:25 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

We did get a little bit of advance warning that these were potentially going to happen. Of course, nothing is cemented until you receive the letter informing you that this is in fact going to be happening.

4:25 p.m.

Conservative

Vincent Ho Conservative Richmond Hill South, ON

Were you consulted, or was it just a notice?

March 23rd, 2026 / 4:25 p.m.

President and Chief Executive Officer, BioCanRx

Stéphanie Michaud

It was a notice.

It highlights the important work this committee is doing with respect to governance and being able to take a step back to examine what seems like an overall small cut and the downstream impact it will have with respect to our individual organizations and the kind of work that we do.

We've been selected in the strategic science fund for very specific reasons to achieve a specific set of results for Canadians.